Would you add ADT to EBRT for favorable intermediate risk patients with T1c prostate cancer by DRE and bilateral prostatic lobe involvement by MRI?  

Let's break down the question: If the patient has favorable intermediate risk disease, but cT1c by DRE, then he must have either: Grade group 2 (Gleason 3+4), PSA <10, and percent positive cores <50%; or Grade group 1 (Gleason 3+3), PSA 10-20, and percent positive cores <50%   ...

Generally speaking, I would not add ADT for a man with favorable, intermediate risk disease treated with EBRT. These men have a high chance for biochemical control, and low chance for cancer mortality (<5%) at 10 years with RT alone, and the added benefit of for ADT is small, probably not making ...

No

Great discussion! The eContouring resources have been great for learning the technical aspects of prostate SBRT/hypofx/MRI fusion after training. The ASTRO refreshers, in my opinion at least, from the mid-2010s were too focused on data minutiae and not practical treatment planning but not sure about...